255 related articles for article (PubMed ID: 35273100)
1. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
2. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
[TBL] [Abstract][Full Text] [Related]
3. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
Front Immunol; 2022; 13():954039. PubMed ID: 36131912
[TBL] [Abstract][Full Text] [Related]
5. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
Capone M; Fratangelo F; Giannarelli D; Sorrentino C; Turiello R; Zanotta S; Galati D; Madonna G; Tuffanelli M; Scarpato L; Grimaldi AM; Esposito A; Azzaro R; Pinto A; Cavalcanti E; Pinto A; Morello S; Ascierto PA
J Transl Med; 2020 Mar; 18(1):121. PubMed ID: 32160899
[TBL] [Abstract][Full Text] [Related]
6. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
7. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
Morello S; Capone M; Sorrentino C; Giannarelli D; Madonna G; Mallardo D; Grimaldi AM; Pinto A; Ascierto PA
J Transl Med; 2017 Dec; 15(1):244. PubMed ID: 29202855
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of PD-L1
Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
[TBL] [Abstract][Full Text] [Related]
13. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
Yang J; Chen J; Liang H; Yu Y
Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
15. Multifunctionality of CD8
Manabe K; Yamasaki O; Nakagawa Y; Miyake T; Udono H; Morizane S
J Dermatol; 2021 Aug; 48(8):1186-1192. PubMed ID: 33890340
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
17. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
18. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function.
Smyth LA; Ratnasothy K; Tsang JY; Boardman D; Warley A; Lechler R; Lombardi G
Eur J Immunol; 2013 Sep; 43(9):2430-40. PubMed ID: 23749427
[TBL] [Abstract][Full Text] [Related]
19. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
[TBL] [Abstract][Full Text] [Related]
20. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.
Clayton A; Al-Taei S; Webber J; Mason MD; Tabi Z
J Immunol; 2011 Jul; 187(2):676-83. PubMed ID: 21677139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
